|
|
|
|
|
|
|
M T W Th Fri |
|
15 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
M&A isn’t just for big pharma anymore. Kyle LaHucik pulls back the curtain on non-traditional shoppers who are taking part in the current biotech-buying bonanza. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placeda full
clinical... | |
|
|
|
 |
|
ASGCT in Boston (Ryan Cross for Endpoints News) |
|
|
|
by Ryan Cross
|
BOSTON — Two nonprofit organizations have devised a plan to help abandoned cell and gene therapies find a new home. On Thursday, the American Society... | |
|
|
|
|
|
|
|
|
by Ryan Cross
|
A gene therapy designed by Encoded Therapeutics reduced seizures by 76% in children with Dravet syndrome, a severe neurodevelopmental disorder. The remarkable reduction was observed only... | |
|
|
|
|
|
